Xiaolin Zhu

Xiaolin Zhu, MD, PhD is an Adjunct Lecturer in the School of Medicine at the University of California, San Francisco (UCSF), specializing in the Genitourinary Medical Oncology Program. His clinical focus is on prostate, bladder, and kidney cancers, while his research explores cancer evolution mechanisms through patient biospecimen analysis. He holds roles as Principal Investigator on grants from the Department of Defense, Prostate Cancer Foundation, and Conquer Cancer Foundation.

• Education:
  • Bachelor of Medicine (MD equivalent) in Clinical Medicine, Shanghai Jiao Tong University School of Medicine (2011)
  • PhD in Genetics and Genomics, Duke University (2017)
  • Internal Medicine Residency, UT Southwestern Medical Center (2020)
  • Hematology/Oncology Fellowship, UCSF (2024)
• Research Interests:

  Focuses on precision oncology, genomic profiling of treatment resistance, and translational research in prostate and urothelial cancers. Key areas include epigenetic evolution in cancer progression, biomarker discovery, and developing novel therapeutic strategies.

• Awards:
  • ASCO Young Investigator Award (2022-2023)
  • PCF Young Investigator Award (2022-2025)
  • Department of Defense Physician Research Award (2024-2028)
• Grants:
  • Investigating SSTR1 as a novel biomarker for advanced prostate cancer (DOD, 2024-2028)
  • Resistance mechanisms to androgen receptor inhibitors (PCF, 2022-2025)
  • Genomic profiling of metastatic castration-resistant prostate cancer (ASCO, 2022-2023)
• Labs/Teams: Active in UCSF's Genitourinary Oncology research teams and collaborates with the West Coast Prostate Cancer Dream Team.